Global Biopharma R&D · Compute Elasticity & Tidal Scheduling 完整分析 / Full Analysis: KAI_com_biopharma_global_tidal_scheduling.md (46.5KB · 10 Countries, 10 Cases)

Core Discovery: Biopharma = KAI.com’s “Killer App”

Natural Fit: Biopharma R&D × Compute Tidal Scheduling: ★★★★★ Pure Batch Nature — Molecular simulation/ virtual screening can naturally queue. Zero Real-Time Constraints — Drug discovery doesn’t require millisecond latency. Perfect Checkpointability — MD simulations naturally save snapshots, interruptible anytime. Global Collaboration Necessity — Diseases know no borders, but data does. Explosive Demand Spikes — Compute demand can surge to 100x during pandemics. Complementary Time Zones — Regions design experiments by day, compute by night. Across 10 cases: 7 are ★★★★★ and 3 are ★★★★☆ in elasticity; none fall below ★★★★☆. In comparison, Defense AI has only 5 ★★★★★ scenarios. • • • • • • • • • • • • KAI.com Global Biopharma R&D Report

I. Overview of Top 10 Global Biopharma Compute Cases

场景 / Scenario

Representative

Peak GPU

Elasticity

Sovereignty

Potential

AI Small Molecule Drug Discovery Recursion (美), Isomorphic (英) Recursion (US), Isomorphic (UK) H100 × 500-2000 ★★★★★

Med $200-500M

Protein Structure Prediction DeepMind (英), Baker Lab (美) DeepMind (UK), Baker Lab (US) H100 × 500-2000 ★★★★★

X-Low $100-250M

Molecular Dynamics Simulation D.E. Shaw (美), RIKEN

D.E. Shaw (US), RIKEN (JP) H100 × 100-500 ★★★★★

Med $150-400M

Genomic Analysis Genomics England

Genomics England (UK), BGI (CN) H100 × 100-1000 ★★★★☆

X-High $300-600M

CRISPR Gene Editing Editas (美), Intellia (美) Editas (US), Intellia (US) H100 × 50-200 ★★★★★

Low $30-80M

mRNA Vaccine Design Moderna (美), BioNTech (德) Moderna (US), BioNTech (DE) H100 × 100-500 ★★★★★

Med $80-200M

Clinical Trial Simulation

Global Top 50 Pharma H100 × 100-500 ★★★★★

L-M $150-400M

Real-World Evidence (RWE) FDA (美), Flatiron (美) FDA (US), Flatiron (US) H100 × 100-1000 ★★★★☆

X-High $100-300M

AI Antibody Design Absci (美), Generate Bio (美) Absci (US), Generate Bio (US) H100 × 200-1000 ★★★★★

Med $80-200M

Natural Product Screening

CACMS (CN), CSIR (IN) H100 × 100-500 ★★★★★

Special $50-150M

总计 / Total $1.24-3.08B KAI.com Global Biopharma R&D Report

II. 24-Hour Global Tidal Scheduling Instance UTC 00:00-06:00

“Asia Sleeps · Americas Peaks” (🌊 Asia 15% → Americas 85%) US Recursion’s virtual screening redirected to idle nighttime H100s in Japan/Singapore. India’s natural product screening dispatched to UAE/Saudi nighttime off-peak data centers. UTC 06:00-12:00

“Global Equilibrium” Regions utilize local compute; KAI.com DELPHI oracle updates global pricing every 60 seconds. UTC 12:00-18:00

“Asia Peaks · Americas Sleeps” (🌊 Americas 15% → Asia 85%) China’s protein structure prediction absorbed fully by US West/East nighttime GPUs. UK’s Genomics England non-sensitive genomic compute scheduled to US nighttime data centers. UTC 18:00-24:00

“Bidirectional Equilibrium” Europe sleeps; compute transitions to Asia’s declining phase, preheating for the next Asian peak.

24-Hour Cycle Results: Global GPU utilization scaled from 45% to 78% (+33 percentage points) Trough compute prices reduced to just 20-40% of peak pricing Overall R&D compute cost savings: 35-50% • • • • • • • • • • • • • • • • • • KAI.com Global Biopharma R&D Report

III. Detailed Scheduling Insights per Case

Case 1: AI Drug Discovery (★★★★★ — Most Mature Market) Recursion Pharmaceuticals Real Data: BioHive-2 supercomputer houses 500 H100s, covering 2.8B compounds (expanding to 14B). Utilization spikes to

90% during screening but plummets to <20% during target validation. This means GPUs are underutilized ~80% of the time—idle capacity that can be monetized globally via KAI.com. Scheduling Mode: Virtual screening is purely batch- driven. A library of 1 billion compounds can be chunked into 10,000 sub-tasks. Recursion designs experiments during US days; KAI.com executes them across global nighttime GPUs, returning results by morning.

Case 2: Protein Structure Prediction (★★★★★ — Ultimate Globalization) This scenario faces the fewest scheduling friction. Protein sequences/structures have long been open scientific public goods (PDB/UniProt). Free from sovereign constraints, model weights can be distributed instantly. Granularity reaches down to a “one protein, one GPU” level. With 200M+ known proteins processed independently, this is KAI.com’s “Bitcoin mining” equivalent.

Case 3: Molecular Dynamics Simulation (★★★★★ — Folding@home Upgraded) Folding@home proved that 2M volunteers can form a 2.4 ExaFLOPS machine. KAI.com upgrades this volunteer model into a paid, highly reliable, and sovereign-compliant commercial cluster. MD simulations save state snapshots every N steps, making them natively interruptible and perfectly suited for Spot/Preemptible instance pools. KAI.com Global Biopharma R&D Report

Case 4: Genomic Analysis (★★★★☆ — Touchstone for Sovereignty) This serves as the definitive test for KAI.com’s JANUS sovereign fence. UK NHS patient data cannot leave national borders but can switch across local data centers. KAI.com aggregates AWS London, GCP London, and Azure UK South into a dynamic pool, enabling “in-country tidal scheduling” where data stays isolated while compute flows internally. 案例五-六：CRISPR + mRNA（★★★★★ ——

Cases 5-6: CRISPR + mRNA (★★★★★ — Elegant Micro-Parallelism) CRISPR: Off-target prediction for each gRNA is entirely self-contained, parallelizing natively to a microscopic “one gRNA, one GPU” format. mRNA: Taking Moderna’s personalized cancer vaccines as an example, every patient’s sequence design is unique. Sensitive clinical profiles are handled within domestic boundaries, while raw mRNA sequence optimization is offloaded to the global pool before returning product data.

Case 7: Clinical Trial Simulation (★★★★★ — Prime Compute Futures Target) Pharma firms maintain strict roadmap visibility: 6 months prior to an NDA/BLA submission, a massive wave of concentrated simulation compute is required. Through KAI.com’s futures marketplace, they can hedge against price fluctuations by locking down compute windows months in advance, representing a mature use case of compute financialization. KAI.com Global Biopharma R&D Report

Cases 8-10: Real-World Evidence + Antibody + Natural Products Real-World Evidence: Stringent data compliance, but NLP extraction from EHRs is inherently offline batchable (★★★★☆). AI Antibody Design: Vast antibody affinity library screenings can be split down to “one sequence, one GPU” parallelism (★★★★★). Natural Product Screening: Traditional knowledge bases (TCM, Ayurveda) carry sovereign sensitivities, but the raw virtual screening calculations can run globally (★★★★★). KAI.com Global Biopharma R&D Report

IV. Why Biopharma is KAI.com’s True “Killer App”

Dimension 国防AI / Defense AI

High Elasticity Ratio

Low Elasticity Count

0 / 10 (Exceptionally high across all)

Peak Sovereignty Barrier

Nuclear/EW (Total physical isolation, zero sharing)

Genomics/EHR (Intracountry multi-cloud scheduling)

Most Borderless Use Case

Biodefense joint collaboration

Protein Prediction (Zero sovereign barriers globally)

Demand Spike Triggers

Conflict/Crises (Rare, highly unpredictable)

Pandemics / Periodic public data releases (Frequent)

Public Good Justification

Often politically sensitive or contested

Universally justified — Promotes global human health

Willingness & ROI

High (Sovereign military budgets)

ROI） High (Pharma commercial budgets + precise ROI)

Market Education Cost

Extremely high (Classified procurement & clearances)

Medium-Low (Acutely accustomed to CRO outsourcing) KAI.com Global Biopharma R&D Report

Key Conclusion: Biopharma R&D ≠ KAI.com’s “Largest Market” (Defense scales higher in capital terms). Biopharma R&D = KAI.com’s “Best Validation Market”. Its perfect data pipelines, minimal policy friction, and mature buyers make it the ideal second pillar alongside Defense AI to demonstrate the paradigm of KAI.com’s “planetary-scale compute scheduling.” This dual-engine drive seals the commercial thesis. KAI.com Global Biopharma R&D Report

V. Five Strategic Value Pillars of KAI.com in Biopharma

① Cost Revolution: Capex Efficiency via Flexible Compute Mid-sized biotech firms requiring peak capacity of 50-200 H100s previously required $15M-60M in infrastructure Capex. Turning to KAI.com shifts this to an Opex model of $3M-15M/year, slashing asset locking by 60-80%. ② Spike Elasticity: Mastering Data Tsunamis & Pandemic Spikes Major events like the UK Biobank data drops generate temporary 50-100x surges in compute demand. KAI.com’s NOSTRADAMUS engine accurately forecasts events a week early, enabling teams to conclude complex maps in 48 hours instead of waiting weeks. ③ Sovereign Compliance: Static Data, Fluid Compute Lines Patient datasets remain permanently stationary in their country of origin (e.g., UK NHS nodes). Only non- identifiable model weights are routed through full-link TEE secure pipelines for worldwide cross-inference, satisfying strict GDPR provisions. ④ Global Collaboration: Federated Edge Architecture Cross-border sovereign data is processed independently at local clusters. Gradient updates are then aggregated globally via KAI.com’s secure fabric, distributing model optimization benefits fairly based on each region’s exact hardware/data inputs. ⑤ Financialization: Compute Futures to Anchor Risk Management Pharma entities can secure 18-month forward pricing structures to bring ironclad predictability to multi-year R&D budgets. Concurrently, early-stage biotechs purchase “compute call options” to safely hedge against spot volatility during clinical rushes. KAI.com Global Biopharma R&D Report

VI. Compute Elasticity Spectrum Across the 10 Cases

🔴 High Elasticity (★★★★★) — Flawless Tidal Candidates: [2] Protein Structure Prediction (Zero sovereign barrier, ideal global distribution) [1] AI Drug Virtual Screening    [5] CRISPR Off-target Prediction [6] mRNA Sequence Optimization    [7] Clinical Trial Group Simulations [9] Large Antibody Library Screenings    [10] Natural Product Isolation Queries 🟡 Med-High Elasticity (★★★★☆) — Tidal Viable under Strict Guardrails: [3] MD Simulation (Heavy GPU workload but chained to inter-node InfiniBand latency) [4] Genomic Deep Analytics (Bound tight by domestic cross-border data laws) [8] Real-World Evidence (RWE) Datasets (Requires close pipeline coupling to live EHR feeds) 🟢 Low Elasticity (≤ ★★★☆☆) — Non-existent: Biopharma exhibits zero scenarios beneath three stars. This comprehensive industry-wide baseline profile grants it unparalleled standing and unique premium value inside global decentralized markets. KAI.com Global Biopharma R&D Report

Appendix: Unified Architecture of Compute Market Making Research Series

报告名称 / Document Name

Thesis

Size preemptible_compute_market_making_report.md

mechanics of compute spot market making 50 KB KAI_com_defense_AI_global_tide_market_maker.md

orchestration of Defense AI assets 59 KB OpenRouter_vs_KAI_com_Strategic_Comparison.md

Structural bifurcation of primary infra networks 27 KB KAI_com_biopharma_global_tidal_scheduling.md

Biopharma R&D tidal resource scheduling 47 KB

总计规模 / Total Consolidated Framework

Matrix 183 KB KAI.com Global Biopharma R&D Report